Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
Status:
Completed
Trial end date:
2020-10-16
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that adding carfilzomib to standard conditioning regimen for
allo-HCT for advanced or high-risk hematologic malignancies will decrease post-transplant
relapse and treatment-related mortality by decreasing severe GVHD, leading to overall
improvement in transplant outcomes.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center